Right to Try Act - Individualized Investigational Treatments
Impact
The passage of HB 676 is expected to modify state laws governing access to investigational treatments significantly. By permitting broader access to treatments not yet fully approved by the FDA, the bill promotes a more personalized approach to healthcare that relies on genetic and biomarker analyses. This legislative change could lead to decreased barriers for patients exploring non-traditional treatment avenues, particularly those with limited options due to their medical conditions. Healthcare providers and patients could benefit from expanded pathways to therapy, aligning with contemporary advances in personalized medicine.
Summary
House Bill 676, known as the Right to Try Act for Individualized Investigational Treatments, aims to broaden the scope of the existing Right to Try Act in Maryland. It allows individuals with life-threatening or severely debilitating illnesses to access individualized investigational treatments that are custom-made based on their genetic profiles. The bill expands the definition of 'eligible patient' and repeals prior restrictions regarding the profitability of drug manufacturers in this context, enabling them to potentially charge for these treatments. Furthermore, insurers and government agencies are authorized to provide coverage for these investigational treatments, which may significantly enhance patient access to cutting-edge therapies.
Sentiment
The sentiment surrounding HB 676 appears largely positive among patient advocacy groups and those supporting personalized medicine initiatives. Proponents argue that the bill empowers patients to take control of their treatment options in dire health circumstances. However, there are concerns about the potential commercialization and safety implications of individualized treatments without full prior FDA approval. Critics may express unease over insurance coverage parameters and the impact this could have on broader healthcare costs and regulation, highlighting the need for careful oversight in implementation.
Contention
Notable points of contention include discussions on the safety and ethical implications of enabling access to investigational treatments that have not undergone full FDA approval processes. Additionally, the bill's allowance for manufacturers to profit from these treatments raises ethical questions regarding potential exploitation of vulnerable patients seeking desperate, life-saving measures. Opponents may argue that this could lead to a 'pay-to-play' scenario where only patients with significant financial resources can access avant-garde treatments, thereby creating disparities in healthcare access.
To Create The Right To Try Individualized Investigational Treatment Act; And To Ensure That Patients Have Access To Individualized Investigational Treatment.
Health care; creating the Right to Try for Individualized Treatments Act; authorizing individualized investigational treatments for eligible patients. Effective date.
Enacting the right to try for individualized treatments act to permit a manufacturer to make an individualized investigative treatment available to a requesting patient.
Health: other; individualized investigational treatment for certain patients suffering from a life-threatening or severely debilitating illness; provide for. Amends title & secs. 1, 2, 3, 4, 5, 6 & 7 of 2014 PA 345 (MCL 333.26451 et seq.) & adds sec. 2a.
To Create The Right To Try Individualized Investigational Treatment Act; And To Ensure That Patients Have Access To Individualized Investigational Treatment.